P5503Long term prosnoctic benefit of complete revascularizaction in elderly non ST elevation myocardial infarction patients

Abstract Background The benefit of complete or culprit vessel revascularization in elderly patients (>75 years) with Acute Coronary Syndrome without ST-segment elevation (NSTEMI), and multivessel disease (MVD) remains debated. Purpose We aimed to study the current long-term prognostic benefit of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European heart journal 2019-10, Vol.40 (Supplement_1)
Hauptverfasser: Abou Jokh Casas, C, Agra Bermejo, R, Cordero, A, Garcia Acuna, J M, Rigueiro Veloso, P, Iglesias Alvarez, D, Alvarez Alvarez, B, Diaz, B, Alvarez Rodriguez, L, Roman Rego, A, Cid Alvarez, B, Cinza Sanjurjo, S, Gonzalez Juanatey, J R
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background The benefit of complete or culprit vessel revascularization in elderly patients (>75 years) with Acute Coronary Syndrome without ST-segment elevation (NSTEMI), and multivessel disease (MVD) remains debated. Purpose We aimed to study the current long-term prognostic benefit of complete revascularization in an elderly population with NSTEMI and MVD. Methods We performed a retrospective cohort study of 1722 consecutive elderly NSTEMI patients. Baseline patient characteristics were examined and a follow-up period was established for the registry of death and first major cardiovascular event (MACE). We performed a propensity-matching analysis to draw up two groups of patients paired according to whether or not they had been completely revascularized. The prognostic value of the revascularization to predict events during follow-up was analyzed using Cox regression. Results Among the study participants, 30.4% (n=524) underwent complete revascularization and 69.6% (n=1198) had culprit vessel revascularization performed. Patients in these groups have different clinical and pharmacological profiles. After the propensity score analysis, the population was divided into two groups: complete revascularization (n=353) and culprit vessel revascularization (n=353).The median follow-up was 45.7 months. All cause mortality (52.1% vs 28.6%, p
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehz746.0453